

13th International Symposium of Targeted Alpha Therapy (TAT13)

I was delighted to receive a PIANOFORTE travel grant to attend the TAT13 conference in Rio de Janeiro, Brazil, where I presented my research as an oral presentation. TAT13 proved to be an outstanding platform for engaging with the targeted alpha therapy community. I had the opportunity to share my work, connect with fellow researchers, and gain exposure to the latest scientific and clinical advances in the field.

One of the most valuable aspects of the conference was the insight I gained into the clinical realities of alpha therapy, including the challenges faced by clinicians in practice when it comes to treating patients with alpha therapy. This perspective deepened my understanding of where preclinical research can make the most meaningful contribution to bridging the gap between bench and bedside. The industry sessions were equally rewarding, offering the chance to network with professionals across radiopharmaceutical development and forge connections that I expect will be of lasting value to my career.

A particular highlight was having my research featured in the conference highlights. It was a meaningful recognition, and increased the visibility of my work within the community. Beyond the scientific programme, I also had the privilege of experiencing Rio de Janeiro, a city whose culture and energy made the trip all the more memorable.

Attending TAT13 was both a professionally enriching and personally rewarding experience. This opportunity would not have been possible without the generous support of PIANOFORTE, and I am sincerely grateful for the funding that made my participation a reality.